¤ OpenAccess: Green

This work has “Green” OA status. This means it may cost money to access on the publisher landing page, but there is a free copy in an OA repository.

Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer

Maha Saad,Olga B. Garbuzenko,Tamara Minko

Multiple drug resistance

Drug

Anticancer drug

2008

To develop a novel nanomedicine approach for the treatment of multidrug-resistant (MDR) cancer by combining an anticancer drug and suppressors of cellular resistance within one multifunctional nanocarrier-based delivery system (NDS).The NDS consisted of cationic liposomes (carrier, 100-140 nm), doxorubicin (DOX, anticancer drug), siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump and nonpump cellular-resistance, respectively). The resulting approximately 500 nm complex has a zeta potential of +4 mV.The NDS provides an effective co-delivery of DOX and siRNA as well as cell-death induction and suppression of cellular resistance in MDR lung cancer cells.We demonstrate NDS-enhanced efficiency of chemotherapy to a level that cannot be achieved by applying its components separately.

Cite this:

Generate Citation

“Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer” is a paper by Maha Saad Olga B. Garbuzenko Tamara Minko published in 2008. It has an Open Access status of “green”. You can read and download a PDF Full Text of this paper here.